COMP <GO>
ONC vs LLY // OPERATING MARGIN
BeOne Medicines Ltd. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: ONC 2
— LLY 12
▲ OPERATING MARGIN LEADER: LLY
LAST: $370.33 (-0.33%) • MKT CAP: $42.25B
operating-margins
8.40%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
operating-margins
40.21%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ONC VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ONC | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.50% | 83.64% | +3.86 | ONC | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.50% | 32.36% | -21.86 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 63.9x | 36.4x | +27.48 | LLY | /valuation <GO> |
| Free Cash Flow Yield | 2.23% | 2.30% | -0.07 | LLY | /fcf-yield <GO> |
| Operating Margin ACTIVE | 8.40% | 40.21% | -31.81 | LLY | /operating-margins <GO> |
| Net Profit Margin | 5.40% | 31.90% | -26.50 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 40.20% | 45.51% | -5.31 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.68 | 9.29 | -2.61 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.77% | +0.03 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.7 | 77.9 | -25.20 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 0.51 | +0.47 | ONC | /macro-sensitivity <GO> |
| Forward P/E Multiple | 123.6x | 26.3x | +97.35 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $42.25B | $1.33T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ONC REV | LLY REV | ONC GROSS % | LLY GROSS % | ONC FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.34B | $65.18B | 87.5% | 83.0% | $941.7M | $16.81B |
| FY 2024 | $3.81B | $45.04B | 84.4% | 81.3% | -$633.3M | $8.82B |
| FY 2023 | $2.46B | $34.12B | 44.0% | 79.3% | -$1.27B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ONC // BETA 0.98
LLY // BETA 0.51